Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C (2010)
Chapter: Appendix B: Public Meeting Agendas
B
Public Meeting Agendas
FIRST MEETING-DECEMBER 4, 2008
National Academy of Sciences Building, Washington, DC
Welcome and opening statement
Palmer Beasley, Committee Chair
Charge to the committee
John Ward, Centers for Disease Control and Prevention (CDC)
Chris Taylor and Martha Saly, National Viral Hepatitis Roundtable
Presentations to the committee
Dale Hu, CDC
Broad Overview of Hepatitis B
Cindy Weinbaum, CDC
Broad Overview of Hepatitis C
Lorren Sandt, Caring Ambassadors Program
Hepatitis C: Moving Beyond the Silence
Joan Block, Hepatitis B Foundation
Hepatitis B: Time for Zero Tolerance
Public comment period
SECOND MEETING-MARCH 3, 2009
The National Academies Beckman Center, Irvine, California
Welcome and opening statement
Palmer Beasley, Committee Chair
Presentations to the committee
Gary Heseltine
Lead Consultant, Viral Hepatitis Team, Council of State and Territorial Epidemiologists
Surveillance Strengths and Weaknesses
William Rogers
Director of CMS, Physician’s Regulatory Issues Team
Viral Hepatitis Prevention Policies and Programs, Centers for Medicare and Medicaid (CMS)
Tanya Pagán Raggio Ashley
Director, Office of Minority Health and Health Disparities, and Chief Medical Officer, HRSA
Community Health Centers: Health Resources and Services Administration (HRSA) Policies and Programs
Daniel Raymond
Policy Director, Harm Reduction Coalition
Hepatitis C Prevention: Harm Reduction
David Bell
Associate Director for Science and Global Activities, Division of Viral Hepatitis, Centers for Disease Control and Prevention
Global Viral Hepatitis Burden: Implications for the US and CDC Response
